Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)

Inclusion Criteria:

1. Tumor types :

2. Newly diagnosed treatment-naïve ovarian cancer patients eligible for surgery orneoadjuvant chemotherapy

3. Newly diagnosed treatment-naïve triple-negative breast cancer patients eligiblefor surgery or neoadjuvant chemotherapy

4. Newly diagnosed treatment-naïve head and neck cancer patients eligible forsurgery

5. Newly diagnosed treatment-naïve vulva cancer (all types) or cervical cancerpatients with (1) stage Ia - IIa1 with nodal metastasis, postoperative positivemargin or parametrial-vaginal involvement, and (2) stage ≥IIa2).

6. Newly diagnosed treatment-naïve sarcoma cancer patients (1) breast angiosarcomaor (2) uterine sarcoma eligible for surgery or systemic treatment

7. Male or female patients ≥ 18 years of age

8. Signed informed consent

Exclusion Criteria:

1. Male or female patients ≤18 years old

2. Patients with any psychological, familial, sociological or geographical conditionpotentially hampering compliance with the study protocol and follow-up schedule

3. Individually deprived of liberty or placed under the authority of a tutor

4. Patients not affiliated to the Social Security System